INCYIncyte CorporationFinished
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer · Metastatic Nonsquamous Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 583 (final count)
- Started
- Sep 11, 2020
- Main results expected
- Dec 15, 2023
- Fully finished
- May 28, 2026
- Results posted
- Feb 6, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival
Measured over: up to 39.1 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04205812 · record last updated 2026-07-06 · checked 2026-11-09 15:47 UTC